Clinical Trials Browser

INDUSTRY × balstilimab × Clear all

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03894215 2026-03-27

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Phase 2 Terminated

211 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06589440 2026-01-15

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 2 Recruiting

70 enrolled

Gastrointestinal

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT05205330 2025-10-29

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Phase 1/2 Active not recruiting

107 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT05608044 2025-09-04

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2 Active not recruiting

234 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1/2 Completed

211 enrolled 29 charts

Gynecologic

Uterine Cervical Neoplasms

NCT05377528 2025-04-30

Study of AGEN1571 in Participants With Advanced Solid Tumors

Phase 1 Completed

22 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05572970 2025-04-30

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Available

Tumor-Agnostic

Neoplasms

NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Phase 1/2 Recruiting

71 enrolled

GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05033132 2024-03-28

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT03495882 2023-07-05

Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Phase 1/2 Completed

154 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05561491 2023-06-22

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Phase 2 Withdrawn

Dermatologic

Melanoma, Neoplasm Metastasis

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT04156100 2022-03-03

A Study in Subjects With Advanced Solid Tumors

Phase 1 Terminated

19 enrolled

Tumor-Agnostic

Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Phase 2 Withdrawn

Sarcoma

Hemangiosarcoma

Clinical Trials

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Study of AGEN1571 in Participants With Advanced Solid Tumors

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

A Study in Subjects With Advanced Solid Tumors

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma